Why the study?
Adherence to non-vitamin K antagonist oral anticoagulants like edoxaban is unsatisfactory and decreases over time in patients with non-valvular atrial fibrillation.
Do proposed remedial dosing regimens reduce total deviation time compared to EHRA recommendations in NVAF patients with missed edoxaban doses?
Do proposed remedial dosing regimens reduce total deviation time compared to EHRA recommendations in NVAF patients with missed edoxaban doses?
Model-informed remedial strategies for missed edoxaban doses offer shorter deviation times from target PK/PD parameters compared to current EHRA guidelines.
Answers are grounded in this paper and cite their sources.
Model-informed dosing may minimize edoxaban PK/PD deviations; hypothesis-generating and should not yet change practice.
Aim: Edoxaban is a non-vitamin K antagonist oral anticoagulant (NOAC) widely used for long-term stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Adherence to NOACs is unsatisfactory and decreases over time. The aim of this study was to explore appropriated remedial dosing regimens for non-adherent edoxaban-treated NVAF patients through the Monte Carlo simulation. Methods: Six proposed regimens were compared with the recommendations in the European Heart Rhythm Association (EHRA) guide regarding the trough total deviation time considering both edoxaban plasma concentration and inactive factor Xa activity. Monte Carlo simulations were performed using RxODE based on the published population pharmacokinetics/pharmacodynamics model. Results: The proposed remedial strategies were different from EHRA recommendations and were related to delay duration. The missed dose can be taken immediately if the delay time is within 11 h. When the delay period is between 12 and 19 h, a half dose followed by a regular dosing schedule is recommended. When the delay time exceeds 19 h, a full dose followed by a half dose is preferred compared to that recommended in the EHRA guide. Our proposed strategies resulted in a shorter total deviation time than EHRA guide. Conclusion: PK/PD modelling and simulation are effective in developing and evaluating the remedial strategies of edoxaban, which could help maximize its therapeutic effect.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: